Dihexa is not FDA-approved and is sold only by research peptide suppliers
It is suitable for cattle, horses, calves, sheep, and goats and can be administered via intramuscular (IM) or intravenous (IV) injection under veterinary guidance
ARA 290 has been evaluated extensively in a wide spectrum of preclinical models, including diet-induced insulin resistance (10), diabetic retinopathy (11), diabetic autonomic neuropathy (12), myocardial infarction (13), chronic heart failure (14), burns (15), traumatic brain injury (16,17) and shock-induced multi-organ failure (18), among others
Few reported side effects at standard doses